多组学分析揭示特发性炎症性肌病亚型特异性机制与生物标志物
该研究对203例汉族特发性炎症性肌病(IIM)患者(含44例验证队列)和18例对照的肌肉组织进行RNA测序、蛋白质组学和代谢组学分析,通过多组学因子分析(MOFA)区分皮肌炎(DM)、免疫介导坏死性肌病(IMNM)和抗合成酶综合征(ASyS),并识别各亚型特异性分子特征和通路,评估其预后意义。
要点
- MOFA区分DM、IMNM和ASyS与对照,分别识别798、748和297个亚型特异性特征和通路。
- DM中干扰素和细胞因子通路上调,与皮肤表现、束周萎缩/坏死、炎症和复发风险相关。
- IMNM中细胞骨架和细胞外基质通路富集与肌肉坏死、再生和炎症正相关,蛋白质水平ECM相关通路预测良好预后。
核心结论
- 该多组学分析阐明了IIM亚型中不同的分子机制,识别了用于个体化预后和治疗的潜在生物标志物。
研究设计与样本
- 对203例IIM患者(含44例验证队列)和18例对照的肌肉组织进行RNA测序、蛋白质组学和代谢组学分析,使用MOFA整合多组学数据,并进行通路富集、ssGSEA、临床特征相关性、ROC曲线和生存分析。
主要发现
- MOFA区分DM、IMNM和ASyS与对照,分别识别798、748和297个亚型特异性特征和通路,并在独立队列中验证。
- DM中干扰素和细胞因子通路上调,11个干扰素相关基因在外显子、内含子保留和蛋白质水平改变,干扰素和细胞因子评分与皮肤表现、束周萎缩/坏死、炎症和复发风险相关。
- IMNM显示肌球蛋白、肌动蛋白和肌钙蛋白基因改变,细胞骨架和细胞外基质通路富集与肌肉坏死、再生和炎症正相关,蛋白质水平ECM相关通路预测良好预后。
- ASyS显示独特代谢特征(核苷、酮类、磷脂酰丝氨酸)和内皮功能障碍,关键代谢调控基因FABP3、AKR1C2、AKR1C3显示多组学改变与坏死、炎症和预后相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Idiopathic inflammatory myopathies (IIM) are autoimmune disorders with distinct subtype features, but their molecular mechanisms remain unclear. This study integrated multiomics data to identify subtype-specific molecular signatures and evaluate their prognostic significance in a Han Chinese IIM cohort. METHODS: RNA sequencing, proteomics, and metabolomics were generated on muscle tissues from 203 patients with IIM (including 44 in a validation cohort) and 18 controls. Differential expression was analysed for exons, intron retentions (IRs), proteins, and metabolites, integrated via multiomics factor analysis (MOFA). Pathway enrichment, single-sample Gene Set Enrichment Analysis (ssGSEA), correlation with clinical features, receiver operating characteristic curve, and survival analyses were conducted. RESULTS: MOFA distinguished dermatomyositis (DM), immune-mediated necrotising myopathy (IMNM), and antisynthetase syndrome (ASyS) from controls, identifying 798, 748, and 297 subtype-specific features and pathways, respectively, which were further validated in an independent cohort. In DM, upregulated interferon (IFN) and cytokine pathways were prominent, with 11 IFN-related genes altered at exon, IR, and protein levels, alongside changes in related metabolites. IFNs and cytokine scores correlated with skin manifestations, perifascicular atrophy/necrosis, inflammation, and relapse risk. IMNM showed changes in myosin, actin, and troponin genes, with enrichment of cytoskeleton and extracellular matrix (ECM) pathways that were positively linked to muscle necrosis, regeneration, and inflammation. Protein-level of ECM-related pathways predicted a favourable prognosis. ASyS displayed distinct metabolic signatures (nucleosides, ketones, phosphatidylserine) and endothelial dysfunction, with key metabolism-regulated genes (FABP3, AKR1C2, AKR1C3) showing multiomics alterations associated with necrosis, inflammation, and prognosis. CONCLUSIONS: This multiomics analysis elucidates distinct molecular mechanisms in IIM subtypes, identifying potential biomarkers for personalised prognosis and therapy.
引用
- Xiao Y, Xie S, Liu Y, et al. Multiomics analysis uncovers subtype-specific mechanisms and biomarkers in idiopathic inflammatory myopathies. Ann Rheum Dis. 2025. PMID: 40935702. doi:10.1016/j.ard.2025.08.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。